ライブ

Clinical OMICsReporter’s Notebook: Are One-Shot Gene Editors Ready to Tackle Chronic Illness?FierceBiotechASCO: Telix tees up pivotal test for Pluvicto challenger while eyeing ‘white space’ on radiopharma canvas FierceBiotechAt ASCO 2026, a ‘paradigm shift’ for a rare gut cancer looms BioPharma DiveRallyBio tries again for reverse merger, this time with Avenzo Endpoints NewsThe cost of a PRV is twice as high as it was three years ago — and it’s likely to stay that way Endpoints NewsEpigenetic editing shows promise against chronic hep B infections FierceBiotechASCO, Ryght AI team up for breast cancer trial site selection Clinical OMICsSMArT Platform Improves Safety and Efficiency of CRISPR Editing in HSPCs Clinical OMICsPancreatic Cancer Drug Doubles Survival While Reducing Side Effects Endpoints NewsShionogi wins US approval for first pill to prevent Covid following exposure BioWorldAppointments and advancements for June 1, 2026 BioWorldFinancings for June 1, 2026

Clinical OMICs 2026年6月1日

SMArT Platform Improves Safety and Efficiency of CRISPR Editing in HSPCs

The platform improves the precision and safety of CRISPR-Cas9 gene editing in human hematopoietic stem and progenitor cells (HSPCs), a development that addresse...

The platform improves the precision and safety of CRISPR-Cas9 gene editing in human hematopoietic stem and progenitor cells (HSPCs), a development that addresses the long-standing difficulty of ensuring that edited stem cells carry only the intended genetic change. The post SMArT Platform Improves Safety and Efficiency of CRISPR Editing in HSPCs appeared first on Inside Precision Medicine .